000119236 001__ 119236
000119236 005__ 20240228145428.0
000119236 0247_ $$2doi$$a10.1016/j.ctrv.2016.11.010
000119236 0247_ $$2pmid$$apmid:28006694
000119236 0247_ $$2ISSN$$a0305-7372
000119236 0247_ $$2ISSN$$a1532-1967
000119236 0247_ $$2altmetric$$aaltmetric:14524425
000119236 037__ $$aDKFZ-2017-00026
000119236 041__ $$aeng
000119236 082__ $$a610
000119236 1001_ $$aBuffart, Laurien M$$b0
000119236 245__ $$aEffects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs.
000119236 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2017
000119236 3367_ $$2DRIVER$$aarticle
000119236 3367_ $$2DataCite$$aOutput Types/Journal article
000119236 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1511334484_28996$$xReview Article
000119236 3367_ $$2BibTeX$$aARTICLE
000119236 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119236 3367_ $$00$$2EndNote$$aJournal Article
000119236 520__ $$aThis individual patient data meta-analysis aimed to evaluate the effects of exercise on quality of life (QoL) and physical function (PF) in patients with cancer, and to identify moderator effects of demographic (age, sex, marital status, education), clinical (body mass index, cancer type, presence of metastasis), intervention-related (intervention timing, delivery mode and duration, and type of control group), and exercise-related (exercise frequency, intensity, type, time) characteristics. Relevant published and unpublished studies were identified in September 2012 via PubMed, EMBASE, PsycINFO, and CINAHL, reference checking and personal communications. Principle investigators of all 69 eligible trials were requested to share IPD from their study. IPD from 34 randomised controlled trials (n=4519 patients) that evaluated the effects of exercise compared to a usual care, wait-list or attention control group on QoL and PF in adult patients with cancer were retrieved and pooled. Linear mixed-effect models were used to evaluate the effects of the exercise on post-intervention outcome values (z-score) adjusting for baseline values. Moderator effects were studies by testing interactions. Exercise significantly improved QoL (β=0.15, 95%CI=0.10;0.20) and PF (β=0.18, 95%CI=0.13;0.23). The effects were not moderated by demographic, clinical or exercise characteristics. Effects on QoL (βdifference_in_effect=0.13, 95%CI=0.03;0.22) and PF (βdifference_in_effect=0.10, 95%CI=0.01;0.20) were significantly larger for supervised than unsupervised interventions. In conclusion, exercise, and particularly supervised exercise, effectively improves QoL and PF in patients with cancer with different demographic and clinical characteristics during and following treatment. Although effect sizes are small, there is consistent empirical evidence to support implementation of exercise as part of cancer care.
000119236 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000119236 588__ $$aDataset connected to CrossRef, PubMed,
000119236 7001_ $$aKalter, Joeri$$b1
000119236 7001_ $$aSweegers, Maike G$$b2
000119236 7001_ $$aCourneya, Kerry S$$b3
000119236 7001_ $$aNewton, Robert U$$b4
000119236 7001_ $$aAaronson, Neil K$$b5
000119236 7001_ $$aJacobsen, Paul B$$b6
000119236 7001_ $$aMay, Anne M$$b7
000119236 7001_ $$aGalvão, Daniel A$$b8
000119236 7001_ $$aChinapaw, Mai J$$b9
000119236 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b10$$udkfz
000119236 7001_ $$aIrwin, Melinda L$$b11
000119236 7001_ $$aStuiver, Martijn M$$b12
000119236 7001_ $$aHayes, Sandi$$b13
000119236 7001_ $$aGriffith, Kathleen A$$b14
000119236 7001_ $$aLucia, Alejandro$$b15
000119236 7001_ $$aMesters, Ilse$$b16
000119236 7001_ $$avan Weert, Ellen$$b17
000119236 7001_ $$aKnoop, Hans$$b18
000119236 7001_ $$aGoedendorp, Martine M$$b19
000119236 7001_ $$aMutrie, Nanette$$b20
000119236 7001_ $$aDaley, Amanda J$$b21
000119236 7001_ $$aMcConnachie, Alex$$b22
000119236 7001_ $$aBohus, Martin$$b23
000119236 7001_ $$aThorsen, Lene$$b24
000119236 7001_ $$aSchulz, Karl-Heinz$$b25
000119236 7001_ $$aShort, Camille E$$b26
000119236 7001_ $$aJames, Erica L$$b27
000119236 7001_ $$aPlotnikoff, Ron C$$b28
000119236 7001_ $$aArbane, Gill$$b29
000119236 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b30$$udkfz
000119236 7001_ $$aPotthoff, Karin$$b31
000119236 7001_ $$avan Beurden, Marc$$b32
000119236 7001_ $$aOldenburg, Hester S$$b33
000119236 7001_ $$aSonke, Gabe S$$b34
000119236 7001_ $$avan Harten, Wim H$$b35
000119236 7001_ $$aGarrod, Rachel$$b36
000119236 7001_ $$aSchmitz, Kathryn H$$b37
000119236 7001_ $$aWinters-Stone, Kerri M$$b38
000119236 7001_ $$aVelthuis, Miranda J$$b39
000119236 7001_ $$aTaaffe, Dennis R$$b40
000119236 7001_ $$avan Mechelen, Willem$$b41
000119236 7001_ $$aKersten, Marie-José$$b42
000119236 7001_ $$aNollet, Frans$$b43
000119236 7001_ $$aWenzel, Jennifer$$b44
000119236 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b45$$udkfz
000119236 7001_ $$aVerdonck-de Leeuw, Irma M$$b46
000119236 7001_ $$aBrug, Johannes$$b47
000119236 773__ $$0PERI:(DE-600)2002084-3$$a10.1016/j.ctrv.2016.11.010$$gVol. 52, p. 91 - 104$$p91 - 104$$tCancer treatment reviews$$v52$$x0305-7372$$y2017
000119236 909CO $$ooai:inrepo02.dkfz.de:119236$$pVDB
000119236 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000119236 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b30$$kDKFZ
000119236 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aDeutsches Krebsforschungszentrum$$b45$$kDKFZ
000119236 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000119236 9141_ $$y2017
000119236 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000119236 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER TREAT REV : 2015
000119236 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119236 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119236 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119236 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119236 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119236 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119236 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119236 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000119236 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000119236 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000119236 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER TREAT REV : 2015
000119236 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000119236 980__ $$ajournal
000119236 980__ $$aVDB
000119236 980__ $$aI:(DE-He78)G210-20160331
000119236 980__ $$aUNRESTRICTED